Asset Details
Do you wish to reserve the book?
Epidemiology of Candidemia and Antifungal Susceptibility in Invasive Candida Species in the Asia-Pacific Region
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Epidemiology of Candidemia and Antifungal Susceptibility in Invasive Candida Species in the Asia-Pacific Region
Do you wish to request the book?
Epidemiology of Candidemia and Antifungal Susceptibility in Invasive Candida Species in the Asia-Pacific Region
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Epidemiology of Candidemia and Antifungal Susceptibility in Invasive Candida Species in the Asia-Pacific Region
2016
Overview
In the Asia-Pacific region, Candida albicans is the predominant Candida species causing invasive candidiasis/candidemia in Australia, Japan, Korea, Hong Kong, Malaysia, Singapore and Thailand whereas C. tropicalis is the most frequently encountered Candida species in Pakistan and India. Invasive isolates of C. albicans, C. parapsilosis complex and C. tropicalis remain highly susceptible to fluconazole (>90% susceptible). Fluconazole resistance (6.8-15%), isolates with the non-wild-type phenotype for itraconazole susceptibility (3.9-10%) and voriconazole (5-17.8%), and echinocandin resistance (2.1-2.2% in anidulafungin and 2.2% in micafungin) among invasive C. glabrata complex isolates are increasing in prevalence. Moreover, not all isolates of C. tropicalis have been shown to be susceptible to fluconazole (nonsusceptible rate, 5.7-11.6% in China) or voriconazole (nonsusceptible rate, 5.7-9.6% in China).
Publisher
Future Medicine Ltd
Subject
/ Antifungal Agents - therapeutic use
/ Candida
/ Candida - isolation & purification
/ Candida albicans - drug effects
/ Candida albicans - pathogenicity
/ Candida glabrata - drug effects
/ Candida glabrata - isolation & purification
/ Candida glabrata - pathogenicity
/ Candida tropicalis - drug effects
/ Candida tropicalis - isolation & purification
/ Candida tropicalis - pathogenicity
/ Candidiasis, Invasive - drug therapy
/ Candidiasis, Invasive - epidemiology
/ Candidiasis, Invasive - microbiology
/ Drug Resistance, Fungal - drug effects
/ Echinocandins - therapeutic use
/ Etiology
/ Fluconazole - therapeutic use
/ Humans
/ Itraconazole - therapeutic use
/ Lipopeptides - therapeutic use
/ Patients
/ Species
/ Trends
